Areplivir, a drug for the treatment of COVID-19, received marketing authorization in the Kyrgyz Republic

Promomed 25 August 2021

Areplivir, recommended by the Ministry of Health of the Russian Federation for the treatment of COVID-19 of any severity, received marketing authorization in the Kyrgyz Republic

On August 11, 2021, Areplivir (favipiravir) produced by Biokhimik JSC (part of the Promomed Group) received marketing authorization in the Kyrgyz Republic Areplivir has a direct antiviral effect and is recommended by the Russian Ministry of Health for the treatment of COVID-19 of any severity. In the course of clinical trials, which began in June 2020 and took place in five medical institutions in Russia under the guidance of full members of the Russian Academy of Sciences, this drug has proven its high efficacy and safety, preventing the progression of coronavirus infection to a severe form.

Promomed Group was one of the first in Russia to receive a permanent registration certificate for a drug against the SARS-COV-2 virus in September 2020, which made it possible to use the drug in outpatient settings. Almost immediately, Favipiravir was included in the methodological recommendations of the Ministry of Health of Russia for the treatment of COVID-19, and according to the order of the Government of the Russian Federation, this drug was included in the List of Vital and Essential Drugs (VED) starting from 21.10.2020.

The availability of GMP certificate, which confirms the compliance of the Biokhimik production complex with the requirements of the Good Manufacturing Practice of the Eurasian Economic Union, made it possible to combine efforts to combat the pandemic in Kyrgyzstan and to provide regular supplies of Areplivir (favipiravir).

PROMOMED GROUP one of the leaders of the Russian pharmaceutical industry and an active participant in the national drug safety system. The company develops, manufactures and promotes up-to-date medicines, focusing its efforts on increasing the effectiveness and improving the safety profile of therapy for the most important diseases, including socially significant ones. Having the powerful biotechnological platform, the Biokhimik JSC (became part of the Group in 2015), which operates in full compliance with GMP standards, the Group is able to quickly and efficiently develop and produce any innovative drugs.

Promomed’s portfolio includes about 200 types of drugs, 80% of which are included in the VED list and in the list of the guidelines for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19) approved by the Russian Ministry of Health. The volume of production in 2020 amounted to 61 million packages of drugs for various purposes. At the end of 2020, the Expert RA rating agency assigned the non-financial company PROMOMED DM LLC a long-term credit rating ruBBB+.

   
Areplivir, a drug for the treatment of COVID-19, received marketing authorization in the Kyrgyz Republic